Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion
- 17 July 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 59 (11), 1655-1663
- https://doi.org/10.1007/s00262-010-0891-4
Abstract
Indoleamine 2,3-dioxygenase (IDO) is generally considered to be immunosuppressive but recent findings suggest this characterization oversimplifies its role in disease pathogenesis. Recently, we showed that IDO is essential for tumor outgrowth in the classical two-stage model of inflammatory skin carcinogenesis. Here, we report that IDO loss did not exacerbate classical inflammatory responses. Rather, IDO induction could be elicited by environmental signals and tumor promoters as an integral component of the inflammatory tissue microenvironment even in the absence of cancer. IDO loss had limited impact on tumor outgrowth in carcinogenesis models that lacked an explicit inflammatory tumor promoter. In the context of inflammatory carcinogenesis where IDO was critical to tumor development, the most important source of IDO was radiation-resistant non-hematopoietic cells, consistent with evidence that loss of the IDO regulatory tumor suppressor gene Bin1 in transformed skin cells facilitates IDO-mediated immune escape by a cell autonomous mechanism. Taken together, our results identify IDO as an integral component of ‘cancer-associated’ inflammation that tilts the immune system toward tumor support. More generally, they promote the concept that mediators of immune escape and cancer-associated inflammation may be genetically synonymous.Keywords
This publication has 49 references indexed in Scilit:
- Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl PyruvateCancer Research, 2010
- Genotyping and Expression Analysis of IDO2 in Human Pancreatic Cancer: A Novel, Active TargetJournal of the American College of Surgeons, 2009
- Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenaseProceedings of the National Academy of Sciences of the United States of America, 2008
- Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinomaZeitschrift für Krebsforschung und Klinische Onkologie, 2008
- Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor MicroenvironmentClinical Cancer Research, 2007
- Indoleamine 2,3-dioxygenase and tumor-induced toleranceJCI Insight, 2007
- Induced sensitization of tumor stroma leads to eradication of established cancer by T cellsThe Journal of Experimental Medicine, 2007
- Decreased Serum Tryptophan Concentration Predicts Poor Prognosis in Malignant Melanoma PatientsDermatology, 2006
- Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancerBritish Journal of Cancer, 2006
- Inflammation and cancerNature, 2002